Paired serum and cerebrospinal fluid (CSF) samples from 10 AIDS patients with and 10 without AIDS dementia complex (ADC) were studied, in an attempt to uncover ADC-associated variation in V3 sequences. Sequences were obtained from four of the patients with and eight of those without ADC. Comparison of the sequences using a resampling technique revealed a significant ADC-associated difference occurring at several amino acid positions. Results from serum and CSF sequences were comparable. These differences may indicate that the virus found in ADC and that in non-ADC patients have different biological properties. Comparison of serum versus CSF sequences within samples from both ADC and non-ADC patients, using the same resampling technique, revealed no clear distinctions. In some patients, the sequence populations in serum and CSF were completely distinct, while in others, there was no difference in distribution. These patterns were not associated with ADC.
To date, the mechanisms underlying the AIDS dementia complex (ADC) have not been identified. The absence of secondary opportunistic infections indicates that the pathological effect may be caused directly by human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system (CNS). However, the neural cells in the CNS appear to be not or only slightly susceptible to infection with HIV-I (Sharpless et al., 1992) , so direct cytopathic effects alone cannot account for the neurological damage. One hypothesis to explain the neuropathological effect proposes that molecular mimicry of HIV and proteins in the brain results in an autoimmune reaction with ensuing tissue damage (Trujillo e t al., 1993; Eddleston et al., 1993) . In the brain, the primary targets of HIV-1 seem to be microglial/macrophage cells (Koenig et al., 1986; Watkins et al., 1990; Wiley et al., 1986) . HIV-1-infected monocyte-type cell lines have been shown to produce neurotoxins (Pulliam et al., 1991; Giulian et al., 1993) . Evidence has also been found for a direct pathological effect of the free glycoprotein gpl20 * Author for correspondence. Fax +31 20 691 6531. e-mail kuiken@amc.uva.nl
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We have compared HIV-1 V3 sequences from patients with and without ADC, focusing on finding a possible association between the occurrence of ADC and the distribution of different sequences from virus found in the peripheral blood and the CNS. Serum and cerebrospinal fluid (CSF) samples, obtained simultaneously from 20 AIDS patients, half of whom had ADC, were analysed. Serum and CSF samples of each patient were collected simultaneously, a CSF cell count was done and the samples were subsequently stored at -70 °C. One CSF sample (patient 14) contained an elevated number of cells (600/ml), which may indicate a leak in the blood-brain barrier.
Genomic RNA was isolated from 50 Ixl serum or CSF according to Boom et al. (1990) . The isolated RNA was converted to DNA using avian myeloblastosis virus reverse transcriptase (RT) (5 U; Boehringer Mannheim). The RT reaction took place in a total volume of 20 ~tl, containing 75 mM-KC1, 50 mM-Tris-HC1 (pH 8-3), 3 mMMgC12, 10mM-DTT, 1 mM-dNTPs, 20U RNase inhibitor (Boehringer Mannheim), 100 ng of primer (SK39, 3'V3NOT or 3'MS2; Synthetic Genetics), and 101al RNA. The final reaction mixture contained 20 mMTris-HC1 (pH 8.4), 50 mM-KC1, 1 mg/ml BSA (Boehringer Mannheim), MgC12 concentrations accord- ing to the titrated optimum for each primer set (3.6 mM for 5'V3NOT and 3'V3NOT, 1.8 mM for 5'KSI and 3'KSI), 100 ng of each primer, 1 mM of each nucleotide (ATP, CTP, GTP, TTP; Pharmacia), and 2 U of Taq polymerase (Perkin Elmer). Cloning and sequencing was done as described previously (Wolfs et al., 1992) . Sequence alignment was done by hand, keeping codons intact when possible. Phylogenetic analysis was done using the PHYLIP package (Felsenstein, 1993) . The neighbour-joining method (Saitou & Nei, 1987) was used to construct a phylogenetic tree based on distances calculated using the Kimura 2-parameter estimation method (Kimura, 1980) . The variability within and between sets of sequences was calculated using Hamming distances (Hamming, 1986) , expressed as percentages of the total sequence length. Positions containing gaps or ambiguities were excluded from all analyses unless otherwise indicated.
From the CSF of eight patients, no RNA could be isolated due to low viral copy numbers (data not shown). CSF sequences were obtained from four patients with, and eight without ADC; serum sequences were available from these patients and five others.
The sequence populations in serum and CSF varied independently: there is no consistent association between the variation in the CSF and that in the serum (Spearman correlation 0.02). The average between-sample variation of the CSF sequences in the ADC group (7"9 %, SD 3'5, n = 4) was less than that in the non-ADC group (11.0 %, SD 4"0, n = 8). There was no significant association of sequence variation with the presence of ADC, nor with the viral load in serum or CSF (data not shown). However, it should be noted that the failure to isolate RNA from the CSF of all patients with low viral load makes these comparisons biased. The phenotype of the virus, predicted on the basis of the V3 sequences (de Jong et al., 1992; Fouchier et al., 1992) , was syncytiuminducing in three patients: the serum sequences of patient 12 (8/8 sequences), 7/8 sequences from the CSF of patient 15, and 2/8 serum and 4/8 CSF sequences of patient 17.
The patterns of variation are very different between patients. An overview of the distribution of the sequences in all patients can be seen in the tree diagram in Fig. 1 . In most patients, the sequences cluster into two or more groups, which sometimes coincide with the serum-CSF distinction. In Fig. 2 , the amino acid consensus of the serum and CSF sequences is shown, with the mean percentage variation (the mean Hamming distance between the clones, expressed as a percentage of the sequence length). Other studies also found distinct V3 sequence populations in serum and CSF from some patients, but not from others. No variable has yet been found to be associated with this difference, neither Short communication disease stage (Keys et al., 1993) , tropism of the isolated virus in peripheral blood monocytes (PBMCs) culture (Keys et al., 1993) , nor the presence or absence of ADC (this study). It is conceivable that the population differences simply reflect a time-lag, much as has been shown to exist between virions from serum and proviral DNA from infected PBMCs (Simmonds et al., 1991) . The patients in whom we see a disparity between serum and CSF would then simply be those where a new population has arisen in the serum, but has not yet penetrated into the CSF.
In order to detect differences between groups of sequences that were not absolutely conserved but that occurred more consistently than expected, an index (named S-index for Separation) was designed that can identify positions which contain different amino acids in the two groups, as well as positions which are conserved in one group and variable in the other. Most standard methods based on comparing consensus sequences or signatures are likely to fail in this case. The index also allows the amino acid differences to be weighted. For the calculation of the S-index, measures of the within-group homogeneity are computed by adding up the number of identical amino acids (or nucleotides), and dividing the value by the number of comparisons (n2). The betweengroup homogeneity is calculated analogously by comparing all amino acids in one group to all amino acids in the other. The between-group homogeneity is then subtracted from the highest within-group homogeneity value, and the resulting S-index gives a position-wise indication of the distinctness of the two sequence groups.
Evaluation of the significance of the index can be done using a resampling technique. A study by Korber et al. (1994) used a similar approach to test the significance of differences in conservation between brain-derived and blood-derived V3 sequences obtained from a number of patients. It yielded interpretable results which could be corroborated using other datasets. In our resampling analyses, results from the original grouping (split) are compared to those from 10000 random splits. For comparison of the splits, we used the same criterion as Korber et al. : a score was considered significant if it was higher than the highest among 10000 random splits. An added requirement for the between-patient scores was that the positions had to be supported by more than two sequences from more than two patients, to minimize the danger of detecting effects that are due to patient selection. All analyses were done twice, once using an unweighted same/different (identity) scoring system and once using scores weighted with the Dayhoff amino acid similarity index (Dayhoff, 1972) , which weights the conservativeness of the amino acid replacements.
The consensus sequences from the CSF of the ADC and non-ADC groups differed at eight amino acid positions (see Fig. 2) ; the serum consensus sequences of these two groups differed at nine positions. Resampling analysis of the CSF sequences, using both weighted and unweighted differences, identified eight positions that were significant, positions 6, 21, 24, 28, 37, 39, 73 and 76; at only two of these positions (24 and 37) the consensus sequences were different. One additional position (65) was significant only in the unweighted analysis. In the serum, the consensus sequences of ADC and non-ADC patients differed at nine positions. In the resampling analysis positions 6, 22, 24, 28, 36, 39 and 73 had significant S-indices using both methods, and position 95 only when using Dayhoffweights. Two of these, positions 6 and 39, were also different in the consensus sequences. Five positions (6, 24, 28, 39 and 73) had significant scores in both serum and CSF. At only two positions did the two weighting schemes yield a different result, namely position 65 in the CSF (significant only using identity scoring) and position 95 in the serum (significant only using Dayhoff weights).
In the positions with a significant difference in both serum and CSF sequences, the differences showed various patterns. Positions 6, 24, 39 and 73 showed differences in conservation: there was more variation in the ADC sequences at positions 39 and 73, and less variation in the ADC sequences at positions 6 and 24. Position 28 is associated with a glycosylation site, which was destroyed more often in the ADC group, but mutations at this position were sometimes (e.g. in both serum and CSF of patient 11) compensated by two amino acid mutations at positions 24 and 26 which together created a new glycosylation site there. Position 36 (only significant in the serum sequences) showed 33 (of 59) K ~ R mutations in the non-ADC group, versus 9/79 in the ADC group; position 37, only significant in the CSF sequences, contained only S in the ADC group, and S, G and R in the non-ADC group. Position 39 was more variable in the ADC group. An overview of positions that had significant S-index scores is presented in Fig. 2 . The differences we found may form an indication that some biological differences exist between virus from patients with and without ADC. It is difficult to interpret this result because so little is known about the influence of individual amino acid mutations on the structure and function of the V3 loop. All positions that were found to be significant were different in at least two patients in one group, which means that the effects reported are not due to variation in a single individual. However, because the sequences in this set are not independent, the results must be interpreted with care.
Recently, another study was published in which V3 sequences from brain material of ADC and non-ADC patients were compared (Powers et al., 1994) . In that study, a very strong association was found between dementia and the presence of a histidine or serine at position 39. The same position was found to be associated with the dementia/non-dementia distinction in our study: in our set, most non-dementia patients had a histidine at that position, while dementia patients had other amino acids. Although no data exist on this subject, it seems unlikely that the difference between brain tissue and CSF could be dramatic enough to explain the discrepancy. Powers & co-workers had already interpreted their data with circumspection, since at position 39 histidine is the most common amino acid in the general population, where AIDS-associated dementia is a rare occurrence. Another position that Powers & co-workers found to be weakly associated with dementia in their sequence set, position 66, showed the same trend in our study (leucine in the dementia, isoleucine in the non-dementia group), but the resampling analyses showed the association to be nonsignificant in the present study.
The resampling method was also used for comparison of the V3 sequences obtained from the serum and CSF. Though the consensus sequences from serum and CSF differed at positions 24, 36, 54, 69 and 90, none of these positions were consistently different between serum and CSF over all patients (not shown). In view of the high variability at some positions, it is likely that some differences between the consensus sequences arise by chance. In analysing the serum/CSF distinction over all patients, only those patients were included from whom both serum and CSF sequences were available, to reduce the probability of significant scores due to patientspecific factors. In the remaining set, consisting of 138 serum and 98 CSF sequences from 12 patients, no positions had a significant S-index score according to the criteria defined above. We then tried to find patterns in the serum/CSF distinction that were shared by some of the patients. To this end we compared serum and CSF sequences of each individual patient, and computed correlations between the S-index scores of each patient over all positions. All correlations calculated in this manner were below 0.35, indicating that there is only slight association between the scores for each patient: no clear patterns related to the serum/CSF distinction are shared by two or more of the patients. There was also no evidence in our data of another suggested distinction between viral populations from the CNS and from other sources, namely greater homogeneity of the V3 sequences from the CNS (Korber et al., 1994) . The variation in both groups was of comparable magnitude, with serum variation smaller in some and larger in other patients. Over all patients, the range of within-sample variability was 0.5 % to 5"3 % for the CSF (median 2"65 %), and 0"8 % to 3.8 % for the serum (median 2.47 %).
There have been a number of earlier searches for differences between HIV envelope sequences found in different tissue types, both in the V3 region (Keys et al., 1993; Epstein et al., 1991; Korber et al., 1994) , the V4 region and the CD4 binding site (Korber et al., 1994; Pang et al., 1991) , and in gp41 (Steuler et al., 1992) . The same picture emerges from all these studies: in some patients, the populations of variants found in different tissue types are distinct, in others they are similar. Local differences in distribution of virus variants are even found between different sections of one tissue type (Delassus et al., 1992; Sala et al., 1994) ; and variants found in blood cells have been found to migrate to brain tissue, where they were absent in an earlier sample (Korber et al., 1994) . These findings indicate that the distinctions found in these studies may be a reflection of random or time-related factors, rather than of tissuedependent biological differences between the virus variants.
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